Aurélie Najm, ACR 2021: B-cell Repertoire as a Predictor of Methotrexate Response
touchIMMUNOLOGY was delighted to speak with Dr Aurélie Najm (University of Glasgow, Glasgow, UK) about B-cell repertoire changes in patients with rheumatoid arthritis and the recent analysis designed to create a nomogram capable of using B-cell repertoire properties to predict response to methotrexate.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The analysis entitled ‘B Cells Repertoire Repartition Predicts Response to Methotrexate at 6 and 12 Months in Naïve RA: A Machine Learning Driven Approach’ (ABSTRACT NUMBER: 0982) was presented at the ACR Convergence, 5-9 November 2021.
- How does the B cell repertoire change in rheumatoid arthritis according to treatment response? (0:19)
- Could you tell us a little about the machine learning based approach you have developed for predicting response to methotrexate? (1:02)
- What were the aims, design of your study assessing this model? (1:57)
- What were the study findings? (2:50)
- What will be the potential impact of this approach on clinical practice? (4:02)
Disclosures: Dr Aurélie Najm has acted as a consultant for BMS, UCB and Chugai; and as a speaker for UCB.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Filmed in coverage of virtual ACR Convergence 2021.
Share this Video
Related Videos In Rheumatoid Arthritis
Kevin Winthrop, ACR 2022: Integrated safety analysis of filgotinib in moderately to severely active rheumatoid arthritis
Filgotinib, is an oral Janus kinase 1 inhibitor approved in Europe, Japan, and the UK for the treatment of patients with moderately to severely active rheumatoid arthritis (RA). In this touchIMMUNOLOGY interview, we caught up with Prof. Kevin Winthrop (Oregon Health & Science University, Portland, OR, USA) to discuss the objectives, methodology and findings from […]
Paul Studenic, ACR 2022: A validation study of the revised ACR/EULAR remission criteria for rheumatoid arthritis
ACR and EULAR endorsed provisional criteria, both Boolean and index-based, to define remission in rheumatoid arthritis over 10 years ago, in 2022 a revision of the remission criteria has been made. touchIMMUNOLOGY were delighted to speak with Dr. Paul Studenic (Medical University of Vienna, Vienna, Austria) to discuss the methodology and findings of the validation […]
Paul Studenic, ACR 2022: The 2022 revision of the ACR/EULAR remission criteria for rheumatoid arthritis
ACR and EULAR endorsed provisional criteria, both Boolean and index-based, to define remission in rheumatoid arthritis (RA) over 10 years ago, in 2022 a revision of the remission criteria has been made. touchIMMUNOLOGY were delighted to speak with Dr. Paul Studenic (Medical University of Vienna, Vienna, Austria) to discuss the limitations of the Boolean and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!